2.95
4.84%
-0.15
After Hours:
2.95
Trevi Therapeutics Inc stock is traded at $2.95, with a volume of 70,183.
It is down -4.84% in the last 24 hours and up +13.03% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
See More
Previous Close:
$3.10
Open:
$3.1
24h Volume:
70,183
Relative Volume:
0.32
Market Cap:
$214.15M
Revenue:
-
Net Income/Loss:
$-29.07M
P/E Ratio:
-9.5161
EPS:
-0.31
Net Cash Flow:
$-31.85M
1W Performance:
-6.65%
1M Performance:
+13.03%
6M Performance:
-3.91%
1Y Performance:
+38.50%
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-12-23 | Initiated | B. Riley Securities | Buy |
Nov-22-22 | Initiated | SVB Leerink | Outperform |
Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
Jun-03-19 | Initiated | Needham | Buy |
Jun-03-19 | Initiated | SVB Leerink | Outperform |
Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock - MSN
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells $33,162.62 in Stock - MarketBeat
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024 - StockTitan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.80 Average Target Price from Analysts - Defense World
Trevi Therapeutics shares rise on bullish analyst initiation By Investing.com - Investing.com Canada
Raymond James initiates Trevi Therapeutics at Outperform, sees first-to-market opportunity for Haduvio - Investing.com Canada
Trevi Therapeutics (NASDAQ:TRVI) Research Coverage Started at Raymond James - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated at Raymond James - Defense World
Insider Selling: Trevi Therapeutics, Inc. (NASDAQ:TRVI) Director Sells 4,555 Shares of Stock - MarketBeat
Trevi therapeutics director Meeker sells shares worth over $13,000 - Investing.com
Trevi Therapeutics to Participate in September Investor and Medical Conferences - Morningstar
Trevi Therapeutics to Participate in September Investor and Medical Conferences - StockTitan
Trevi Therapeutics executive sells shares worth over $48,000 - Investing.com India
Trevi Therapeutics executive sells shares worth over $48,000 - Investing.com
Trevi Therapeutics executive sells shares worth over $48,000 By Investing.com - Investing.com UK
Trevi Therapeutics (NASDAQ:TRVI) Upgraded to "Strong-Buy" at EF Hutton Acquisition Co. I - MarketBeat
EF Hutton Acquisition Co. I Upgrades Trevi Therapeutics (NASDAQ:TRVI) to Strong-Buy - Defense World
Trevi Therapeutics Provides Business Updates - GuruFocus.com
EF Hutton initiates coverage on Trevi Therapeutics shares with Buy rating - Investing.com Canada
Price T Rowe Associates Inc. MD Purchases Shares of 13,561 Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Thomas Sciascia Sells 18,660 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock - Defense World
Trevi Therapeutics executive trades over $130k in company stock By Investing.com - Investing.com Australia
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Insider Thomas Sciascia Sells 18,660 Shares - MarketBeat
Trevi Therapeutics executive trades over $130k in company stock - Investing.com
Trevi Therapeutics executive trades over $130k in company stock By Investing.com - Investing.com UK
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Vanguard Group Inc. - Defense World
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Expected to Earn Q3 2024 Earnings of ($0.09) Per Share - MarketBeat
Trevi Therapeutics to Participate in Upcoming September Events - GuruFocus.com
B. Riley Research Analysts Decrease Earnings Estimates for Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Longview News-Journal
Trevi Therapeutics Announces the Initiation of its Phase 2b CORA - GuruFocus.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Trevi Therapeutics reports progress in chronic cough trials By Investing.com - Investing.com Australia
Earnings call: Trevi Therapeutics reports progress in chronic cough trials - Investing.com
Earnings call: Trevi Therapeutics reports progress in chronic cough trials By Investing.com - Investing.com Canada
Trevi Therapeutics, Inc. (TRVI) Q2 2024 Earnings Call Transcript - Seeking Alpha
Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023 - Quantisnow
TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q2 2024 - InvestorPlace
Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance - Manchestertimes
Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance - PR Newswire
Trevi Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Trevi Therapeutics Announces Pricing of $[50 Million] Public Offering - Quantisnow
Institutional investors in Trevi Therapeutics, Inc. (NASDAQ:TRVI) see US$40m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
TRVITrevi Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Thursday - MarketBeat
Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024 - Marketscreener.com
Chronic Refractory Cough Pipeline 2024 | GSK, Trevi Therapeutics - openPR
Work at The Globe - The Globe and Mail
Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024 – Company AnnouncementFT.com - Financial Times
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Trevi Therapeutics Inc Stock (TRVI) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
GOOD JENNIFER L | President & CEO |
Sep 04 '24 |
Option Exercise |
1.43 |
10,981 |
15,703 |
224,294 |
GOOD JENNIFER L | President & CEO |
Sep 03 '24 |
Option Exercise |
1.43 |
3,863 |
5,524 |
217,176 |
GOOD JENNIFER L | President & CEO |
Sep 05 '24 |
Sale |
3.11 |
40,277 |
125,310 |
213,313 |
GOOD JENNIFER L | President & CEO |
Sep 04 '24 |
Sale |
3.02 |
10,981 |
33,205 |
213,313 |
GOOD JENNIFER L | President & CEO |
Sep 03 '24 |
Sale |
3.02 |
3,863 |
11,677 |
213,313 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):